When to Refer Diabetic Nephropathy to Nephrology
Refer patients with diabetic nephropathy to nephrology when eGFR is <30 mL/min/1.73 m² (Stage 4 CKD or worse), as this threshold has been shown to reduce costs, improve quality of care, and delay dialysis. 1
Clear Referral Thresholds Based on eGFR
Mandatory Referral
- eGFR <30 mL/min/1.73 m²: This is the most consistent recommendation across all major guidelines 1, 2, 3, 4, 5. At this level of kidney function (Stage 4 CKD), nephrology consultation has demonstrated improved outcomes and cost-effectiveness.
Consider Referral at eGFR 45-60 mL/min/1.73 m²
Refer if any of the following features suggest non-diabetic kidney disease 1:
- Type 1 diabetes duration <10 years
- Absence of diabetic retinopathy (especially in type 1 diabetes)
- Active urinary sediment (red or white blood cell casts, RBCs >20 per high-power field)
- Heavy proteinuria (>6 g/day or nephrotic syndrome)
- Rapid decline in GFR (≥5 mL/min/1.73 m² loss per year) 6
- Abnormal findings on renal ultrasound
- Persistent hematuria (micro- or macroscopic)
Albuminuria-Based Referral Criteria
Refer when albuminuria ≥300 mg/g (UACR) is persistent, particularly if: 2, 7
- Continuously increasing despite ACE inhibitor/ARB therapy 4, 5
- Difficulty achieving ≥30% reduction in albuminuria with standard therapy 4
- Questions about etiology of albuminuria 2
The 2014 KDOQI guidelines recommend referral at ACR ≥300 mg/g 2, though the Canadian guidelines suggest a higher threshold of proteinuria >1 g/day (ACR ≥60 mg/mmol or PCR ≥100 mg/mmol) may be more practical, as kidney biopsy and immunosuppressive therapy are generally not indicated below this level 7.
Management Complexity Triggers
Refer for difficult management issues including: 1
- Resistant hypertension (requiring ≥4 antihypertensive agents) 2
- Persistent electrolyte abnormalities (hyperkalemia or hypokalemia)
- Anemia of CKD
- Secondary hyperparathyroidism or metabolic bone disease
- Side effects or contraindications to ACE inhibitor/ARB therapy despite albuminuria >300 mg/g 2
Progressive Disease Indicators
Refer immediately for continuously decreasing eGFR and/or continuously increasing urinary albumin levels 4, 5. This includes:
- Abrupt sustained fall in GFR (>20% decrease after excluding reversible causes) 7
- Acute kidney injury without clear reversible cause 2
Important Caveats
When NOT to Refer
- Stable, isolated eGFR <30 mL/min/1.73 m² in very elderly patients with clear diagnosis and short life expectancy may not require formal referral—specialist advice may suffice 2, 7
- Normal blood pressure, normal UACR (<30 mg/g), and normal eGFR: No referral needed for primary prevention 4
Common Pitfalls to Avoid
- Late referral: The most recent guidelines emphasize that 29-57% of patients are still referred at Stage 5 CKD 8, which is too late to optimize pre-dialysis care
- Missing non-albuminuric diabetic nephropathy: Up to 50% of diabetic patients with reduced kidney function have normal urinary protein levels 6—don't rely solely on albuminuria for screening
- Assuming all kidney disease in diabetes is diabetic nephropathy: Alternative diagnoses should be considered, especially with atypical features 6, 3
Monitoring Schedule While Awaiting Referral
eGFR 30-44 mL/min/1.73 m²: 1
- Monitor eGFR every 3 months
- Monitor electrolytes, bicarbonate, calcium, phosphorus, PTH, hemoglobin, albumin every 3-6 months
eGFR 45-60 mL/min/1.73 m²: 1
- Monitor eGFR every 6 months
- Monitor electrolytes, bicarbonate, hemoglobin, calcium, phosphorus, PTH at least yearly
The 2020-2025 ADA Standards emphasize that primary care providers should not delay patient education about progressive kidney disease, benefits of blood pressure and glucose control, and potential need for renal replacement therapy while awaiting nephrology consultation 1, 3.